Chargement...

Robocath’s joint venture, Cathbot, concludes first clinical study in China to evaluate robotic PCI safety and efficacy

20 July 2022
End of study brings Robocath closer to commercializing R-One in China in 2023 149 patients enrolled over six months in four Chinese centers Results of first vascular robotics study on this scale in China will be published in March 2023

 

Rouen, France, July 20 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that its joint venture, Cathbot, established in 2020…

Learn more

Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

18 May 2022
100% clinical success rate: zero complications linked to robot up to 30 days post-procedure >95% technical success rate 84.5% average reduction in physician radiation exposure

 

Rouen, France, May 18, 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today presents the results of its R-Evolution clinical study at the international EuroPCR conference. The study, which included 62 patients across six European centers,…

Learn more
Subscribe to our newsletter